Hims & Hers UK Limited
Wholesale of pharmaceutical goods · Bristol
ActiveUnited KingdomIncorporated 2018Private Limited Company
Financial position
Accounts to 2025-12-31 · GBP · Company accounts
Net assets
£13,901,981
Cash
£4,298,719
Turnover
£23,855,340
Profit / loss
£5,048,170
Current assets
£6,404,216
Creditors < 1 year
£1,552,087
Equity
£13,901,981
Average employees
Not available
Balance-sheet trend
GBP · companyFinancial statements
Selected figures from the best-ranked available filing for each period. Missing values remain unknown.
Some figures were read by AI from scanned accounts, so small errors are possible. View the filed accounts
| Reported figures | 2025-12-31Company · AI-read | 2024-12-3112 months · Company | 2023-12-3112 months · Company | 2022-12-3112 months | 2021-12-3114 months | 2020-10-3112 months | 2019-10-3113 months |
|---|---|---|---|---|---|---|---|
| Balance sheet | |||||||
| Net assets | £13,901,981 | £5,954,587 | −£6,708,278 | — | −£332,103 | −£168,985 | −£43,976 |
| Equity | £13,901,981 | £5,954,587 | −£6,708,278 | −£2,815,209 | — | −£168,985 | — |
| Share capital | £313 | — | — | — | — | — | — |
| Retained earnings | −£2,530,540 | — | — | — | — | — | — |
| Assets | |||||||
| Fixed assets | £9,049,852 | £113,677 | £106,314 | £0 | — | — | — |
| Intangible assets | — | £0 | £4,578 | £0 | — | — | — |
| Property, plant & equipment | £105,670 | £113,677 | £101,736 | £0 | — | £861 | £1,010 |
| Investments | £2,177,876 | — | — | — | — | — | — |
| Current assets | £6,404,216 | £7,440,979 | £1,353,340 | £891,733 | £192,319 | £121,516 | £26,082 |
| Cash at bank | £4,298,719 | £6,272,954 | £511,305 | £487,513 | £130,020 | £43,899 | £11,463 |
| Debtors | £1,865,524 | — | — | £404,220 | £62,299 | £72,281 | £14,619 |
| Stock | £239,973 | £220,623 | £138,929 | — | — | £5,336 | — |
| Liabilities | |||||||
| Creditors within one year | £1,552,087 | £1,600,069 | £8,167,932 | £3,706,942 | £524,422 | £243,862 | £71,068 |
| Creditors after one year | — | — | — | — | — | £47,500 | — |
| Net current assets | £4,852,129 | £5,840,910 | −£6,814,592 | −£2,815,209 | −£332,103 | −£122,346 | −£44,986 |
| Assets less current liabilities | £13,901,981 | £5,954,587 | −£6,708,278 | −£2,815,209 | — | −£121,485 | −£43,976 |
| Profit & loss | |||||||
| Turnover | £23,855,340 | — | — | — | — | — | — |
| Cost of sales | £5,365,300 | — | — | — | — | — | — |
| Gross profit | £18,490,040 | — | — | — | — | — | — |
| Administrative expenses | £15,260,359 | — | — | — | — | — | — |
| Operating profit | £3,210,473 | — | — | — | — | — | — |
| Interest receivable | £47,323 | — | — | — | — | — | — |
| Profit before tax | £3,257,796 | — | — | — | — | — | — |
| Tax | £1,790,374 | — | — | — | — | — | — |
| Profit / loss | £5,048,170 | — | — | — | — | — | — |
| Operating costs | |||||||
| Depreciation | £33,428 | — | — | — | — | — | — |
| Audit fees | £22,500 | — | — | — | — | — | — |
| People & pay | |||||||
| Average employees | — | 4 | 4 | 4 | 3 | 1 | 1 |
| Staff costs | £892,705 | — | — | — | — | — | — |
| Wages & salaries | £521,754 | — | — | — | — | — | — |
| Social security costs | £344,863 | — | — | — | — | — | — |
| Pension costs | £26,088 | — | — | — | — | — | — |
| Source evidence | View filing | View filing | View filing | View filing | View filing | View filing | View filing |
From the accounts
What the accounts for 2025-12-31 say about themselves, read by AI from the scanned filing.
- Principal activity
- The principal activity of the Company continued to be that of online sales of health and wellness prescription products and services.
- What it does
- online sales · health and wellness · prescription products · telehealth consultations · personalised healthcare services · sexual health · hair growth · weight loss (AI keywords)
- The year
- During the year, the Company continued to expand its presence in the UK market through customer acquisition initiatives and increased brand awareness, while also driving growth within its existing customer base. Increased adoption of personalised treatment offerings contributed to improve revenue per customer, reflecting ongoing optimisation of product mix and customer experience.
- Outlook
- The Company’s strategy remains focused on expanding its customer base, increasing customer lifetime value, and broadening its range of services within the UK market. Continued investment in technology, product development, and strategic partnerships is expected to support scalable growth and enhance the Company’s ability to deliver accessible, personalised healthcare solutions. The Company continues to evaluate opportunities to introduce additional product lines and services aligned with market needs and regulatory frameworks.
- Auditor
- TC Group
- Audit opinion
- Clean (unmodified)
- Immediate parent
- Hims, Inc. · Delaware, United States of America
- Ultimate parent
- Hims & Hers Health, Inc · Delaware, United States of America
- Ultimate controlling party
- Hims & Hers Health, Inc
- Accounts
- Medium-sized company · FRS 102
- Approved
- 2026-07-24, signed by I Becklund
Subsidiaries (1)
- Health Bridge Limited · 100% · 46 Essex Road, London, England, N1 8LN · Provision of online healthcare services.
Turnover by segment (2)
- Sale of goods: 23,855,340 (2025-12-31)
- Sale of goods: 20,994,831 (2024-12-31)
Acquisitions (1)
- Health Bridge Limited · 100% · £2,177,876
Shares issued in the year (1)
- one (1) ordinary share · for non-cash consideration valued at £2,177,876 · 2025-11-26
Share classes (1)
- 3,132,466 Ordinary share capital of £0.0001
Principal risks (7)
- Regulatory and compliance risks
- Legal risks related to the launch of weight loss offerings
- Reliance on a limited number of third-party suppliers and pharmacies
- Foreign exchange rates and interest rates
- Credit risk
- Liquidity risk
- Inflation and declining consumer spending
Events after the year end (1)
- Subsequent to the year end, the Company entered into a lease agreement for a warehouse facility on 18 May 2026, with lease commencement from 18 May 2026.
Contingent liabilities (1)
- The Company will indemnify SpectrumX Direct Ltd, subject to a cap of £10.0 million, against any and all losses arising from claims alleging that the products compounded for Hims & Hers UK Limited infringe any UK patents. The Company estimates the value of this exposure to be £1,057,661.
Secured borrowing
Registered charges, lenders and security interests.
Charges and related records
0 outstanding chargesNo charges available in our records.